

Risk Factors of Major Depressive Disorder in Parkinson's Disease

Khalil MI^{1*}, Rahman MR¹, Munira S¹, Jahan MU²

¹*Shaheed Suhrawardy Medical College and Hospital, Sher-E-Bangla Nagar, Dhaka, Bangladesh*

²*Consultant Radiologist, Dhaka, Bangladesh*

Abstract

Depression in idiopathic Parkinson's disease is highly prevalent that can significantly impair the quality of life. Its exact mechanism of development is still poorly understood. It is well studied in western population but data from Asia especially in the South Asian region is limited. Considering this, to identify the potential risk factors of depression, a cross-sectional study was conducted among Parkinson's disease patients attending a tertiary care hospital in Bangladesh between July 2013-June 2014, in the Department of Neurology, ShaheedSuhrawardy Medical College and Hospital in Dhaka, Bangladesh. One hundred thirty seven cases of Parkinson's disease were enrolled, based on UK Parkinson's Disease Society Brain Bank criteria. Brain MRI was done in all cases, and patients with aphasia, significant cognitive deficits, secondary Parkinsonism were excluded. The overall prevalence of depression in the study population was 42%. There were no significant differences in gender, residence, education, smoking and marital status. In univariate analysis, age \geq 70 years, un-employed, right side predominantly involved, disease duration \geq 5 years, sleep disturbance, postural instability, dose of levodopa \geq 500 mg/day, Hoehn and Yahr stage \geq III and moderate to severe disability were significantly associated with depressive disorder. Whereas in multivariate linear stepwise regression model, age \geq 70 years), $p=0.044$), right side predominant involvement ($p<0.001$); sleep disturbance ($p=0.006$) and dose of levodopa \geq 500 mg/day ($p<0.001$) were the major risk factors for depressive disorder. A significant proportion of Parkinson's disease patients suffer from depression. It was identified that depression in Parkinson's disease was significantly associated with advancing age, predominate right side involvement, sleep disturbance and higher daily dose of levodopa.

Keywords: Risk factor, Parkinson's disease, Depressive disorder

Introduction

Idiopathic Parkinson's disease (PD) is the second mostcommon neurodegenerative disease affecting about 1% of the population over the age 50, up to4% over the age 80.¹⁻³ The disease is expected to rise proportionately with the increasing of aging worldwide.⁴ The aetiology of PD is currently unclear and the curable treatment is still not available.⁵ Depression is one of the major health problems in patients with PD.^{6,7,38,39} Although, PD primarily is a movement disorder, depression in PD is difficult task and the predictors are complex and debatable.^{8,38} The true prevalence of depression in PD is difficult to determine because there are no standardized assessment tools designed to evaluate depressive symptoms in the context of this disease.^{9,43,44} Depending on diagnostic criteria used, the estimated prevalence of depression in PD has varied widely across studies, from 2.7% to more than 90%, with an average prevalence of about

30-40%.^{3,10-13,49} Despite this high prevalence, unfortunately, depression remains frequently under recognized and often undertreated.^{14,38} Overlap between symptoms and signs of depression, with those of PD, may mask diagnosing depression or PD in its early stages.¹⁵ This also contributes to difficulties interpreting depression rating scales and the absence of standard criteria for depression in PD.^{16,17} Depression appears to be one of the most important factors impairing both subjective and objective quality of life, independent of motor deficits. Thus evaluating depression and identifying risk factors for developing depression is important.^{3,18-20} Depression also has an impact on motor deficits, disability, caregiver burden, economic strain, cognitive impairment and severity of medical illness.^{21,22,38,40,41} It is likely that depression in PD is multifactorial which includes age, sex, disease severity, longer disease

duration, a younger PD onset age, frequent fall, lower education level, smoking and regular use of non-aspirin bases NSAIDs or analgesics.²³⁻³¹ Whereas a recent study reported that PD patients with depression were associated with different demographic and clinical factors.³⁸⁻⁴¹ These findings emphasize the need to study the factors associated with depression in this population. It is well studied in western population but data from Asia especially sub-continent is limited. Findings from the western population cannot be directly extrapolated to the population of this region due to significant sociocultural differences. This may also be supported by the observation that rates of depression have been shown to vary widely between different countries.^{1,2,4,38} However, clinical and socio-demographic risk factors for this comorbidity are not well studied. The intention of this study was to examine possible risk factors of major depressive disorder among the patients with PD in the regional context at a tertiary teaching and referral hospital of Bangladesh.

Materials and Methods

This cross-sectional study was conducted at the outpatient of Department of Neurology, Shaheed Suhrawardy Medical College and Hospital, a teaching and tertiary referral centre in Dhaka, Bangladesh, during July 2013 to June 2014. One hundred thirty seven PD patients were diagnosed clinically, based on the UK Parkinson's Disease Society Brain Bank criteria.^{37,42} A written consent from all participants was taken prior to data collection. Patients with aphasia, significant cognitive deficits affecting participation and refused to participate were excluded. MRI of brain was done in all cases and secondary Parkinsonism was excluded. The Ethics Committee of the Bangladesh Medical Research Council approved the protocol.

The diagnosis of depression was based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) using the structured clinical interview for DSM-IV.⁵⁰ Severity of disease was evaluated by the Hoehn and Yahr stage (H-Y I to V) and modified Rankin Scale (mRS) was used to measure disability (0-1 mild, 2-3 moderate, and 4-5 severe).^{51,52} The rating was done by Neurologist based on the

information obtained from the patient and care giver. A pre-designed questionnaire was used to collect socio-demographic and other clinical information. The interview was conducted in local language and assessments were made in English by the investigators. Tobacco consumption was categorised according to the WHO as: non-smoker, ex-smoker and current smoker and employed was established currently or was employed in last one year.

The data were analyzed through SPSS version 21.00. Continuous variables were expressed as mean \pm standard deviation and were evaluated by the unpaired Student's t test. Similarly, categorical variables were expressed as percentage of the total and were evaluated by the chi-square test to measure the level of significance. Odds ratios and their corresponding 95% confidence limits were determined by logistic regression. A *p* value <0.05 was considered statistically significant. Adjusted odds ratio (adj. OR) between two groups, depression (Group A) and non-depression (Group B) were calculated. All significant variables were entered into a linear regression model in a stepwise fashion and a final fitted model was determined.

Results

One hundred thirty seven cases were enrolled, fifty-seven had depression according to DSM-IV criteria. Thus, the prevalence of depression in this population was 42%. Mean (SD) age of the depressed and non-depressed patients was 70(SD ± 11.6) and 64(SD ± 8.8) years respectively with a range of 45-95 years. Age was significant predictor of depression in linear regression analysis. Majority (37%) of the patients in depressed group were 70 -79 years age group. Male respondents were more in both group A and B (71.9% vs. 76.3%). In employment status, 86% in the depression group was unemployed (table I).

On the basis of residence, education, smoking status, there was no statistical significance between groups where to be found.

Right side was the major side that involves predominantly than left (81% vs. 30%). According to H-Y stage, 39% in non-depressed group in stage two and 40% in depressed group were in stage four (table II).

Table I: Socio-demographic characteristics (Group A= Depression; Group B=Non-depression)

	Group		p
	Group A (n=57)	Group B (n=80)	
Gender			
Male	41	61	0.568
Female	16	19	
Age			
< 50	01	03	0.001
50-59	11	20	
60-69	12	38	
70-79	21	15	
≥80	12	04	
Marital Status			
Married	48	60	0.276
Other	09	20	
Employment Status			
Employed	08	23	0.042
Unemployed	49	57	
Residence			
Urban	26	41	0.591
Rural	31	39	
Education			
Illiterate	16	22	0.134
Primary	18	17	
Secondary	16	17	
HigherSecondary	02	08	
Graduate and above	05	16	
Smoking(only inmale)			
Smoker	21	25	0.415
Non-Smoker	20	36	

*Chi square test was done to measure the level of significance

Table II: Clinical characteristics (Group A= Depression; Group B=Non-depression)

	Group		p
	Group A (n=57)	Group B (n=80)	
Disability(mRS)			
Mild	12	55	<0.001
Moderate	26	21	
Severe	19	04	
Sleep disturbance			
Yes	43	33	<0.001
No	14	47	
Postural instability			
Yes	22	09	<0.001
No	35	71	
Severity (H-Y stage)			
Stage I	05	26	<0.001
Stage II	08	31	
Stage III	14	16	
Stage IV	23	05	
Stage V	07	02	
Predominant side involvement			
Right side	46	24	<0.001
Left side	11	56	

*Chi square test was done to measure the level of significance

Distribution of disability according to modified Rankin scale in Group A and B was found, mild (21% vs. 69%), moderate (46% vs. 26%) and severe (33% vs. 5%) which was statistically significant. The longest duration of PD encountered was 15 years. Mean (SD) disease duration was 6.71 (SD±3.02) and 3.48 (SD±2.02) years in groups respectively and was significant. Sleep disturbance and postural instability were found more in depressed group (table II). Mean (SD) doses of levodopa was 506.14

(SD ±176.04) and 286.56 (SD±202.75) mg/day in groups respectively, which was statistically significant.

Table III: Factors associated with depression (Unadjusted risk distribution)

Variables	Un adj. OR	95% CI	p
Age (years)			
<70 (Ref)	1		
≥70	4.414	2.12 - 9.22	<0.001*
Employment Status			
Employed(Ref)	1		
Un- employed	2.471	1.01 - 6.02	0.046*
Predominant side involvement			
Left side (Ref)	1		
Right side	9.758	4.32 - 22.0	<0.001*
Disease duration(years)			
< 5 (Ref)	1		
≥ 5	7.030	3.24 - 15.27	<0.001*
Sleep disturbance			
No(Ref)	1		
Yes	4.374	2.07 - 9.26	<0.001*
Postural instability			
No(Ref)	1		
Yes	4.959	2.07 - 11.89	<0.001*
Drug dose of Levodopa (mg/day)			
< 500(Ref)	1		
≥ 500	7.199	3.36 - 15.44	<0.001*
Severity(H-Y stage)			
Upto Stage II(Ref)	1		
Stage ≥ III	8.388	3.82-18.40	<0.001*
Disability(mRS)			
Mild(Ref)	1		
Moderate to severe	8.250	3.73 - 18.23	<0.001*

*Statistically significant variables Unadj= Unadjusted

In univariate analysis (table-III), age ≥70 [OR=4.41, 95% CI(2.16-9.22); $p < 0.001$], un-employed [OR=2.47, 95% CI(1.01-6.02); $p = 0.046$], involving right side predominantly [OR=9.76, 95% CI(4.32- 22.00); $p < 0.001$], disease duration ≥ 5 years [OR = 7.03, 95% CI (3.24-15.27); $p < 0.001$], having sleep disturbance [OR= 4.37, 95% CI (2.07- 9.26); $p < 0.001$], postural instability [OR = 4.96, 95%CI(2.07-11.89); $p < 0.001$], daily drug dose of levodopa ≥ 500 mg [OR=47.20, 95% CI (3.36- 15.44); $p < 0.001$], H-Y stage ≥ III [OR=8.39, 95% CI (3.82-18.40); $p < 0.001$], moderate to severe disability [OR = 8.25 , 95 % CI (3.73 - 18.23) ; $p < 0.001$] were statistical significant association with depression.

Table IV: Multivariate linear logistic regression: most significant factors associated with depression

Variables	Adj. OR (95% CI)	p value
Age (years)		
<70 (Ref)	1	
≥70	2.823(1.03-7.76)	0.044
Predominant side involvement		
Left side(Ref)	1	
Right side	17.134(5.55-52.93)	<0.001
Sleep disturbance		
No(Ref)	1	
Yes	4.220 (1.527-11.664)	0.006
Drug dose of Levodopa (mg/day)		
< 500(Ref)	1	
≥ 500	9.820(3.227-29.886)	<0.001

Adj. = Adjusted

When all significant variables were entered into a multivariate linear logistic regression mode (table IV), age ≥ 70 years [OR=2.82, 95% CI (1.03-7.76); $p=0.044$], predominantly involvement in right side [OR=17.13, 95% CI (5.55-52.93); $p<0.001$], sleep disturbance [OR=4.22, 95% CI (1.53-11.66); $p=0.006$] and daily drug dose of levodopa ≥ 500 mg [OR=9.82, 95% CI (3.23-29.89); $p<0.001$] were the major risk factors for the development of depression.

Discussion

According to the results of this study, depression is highly comorbid with PD. These results are in accordance with Asian and Western populations.^{24, 32-34,38,39,46} But studies in clinic-based samples or using different instruments have been reported a wide range of depression rates.^{3,10,11,20,21,47} The prevalence of depression among PD patients depends on the population examined and the definition of depression used for the study. The present study used DSM-IV, based clinical interview, a widely used instrument for depression assessment in comparison to the majority of studies done in Asia.

It may be mentioned here in this study, it could not possible to address depression in PD patients with cognitive impairment or to the patients otherwise unable to utilize self-report instruments for data collection. Furthermore, the severity of depression was not evaluated.

Mean age of this study population had similarity with other studies.^{12,14,24,34,35,38,40,48} Among the examined patient, most of the depression group was un-employed due to old age. It could not to be found an association between major depressive disorder in PD and in frequency of gender, residence, education, smoking and marital status. Another study from Asia also could not to be found any association.³⁸

It was analysed to determine factors contributed for depression. In stepwise fashion, multivariate linear logistic regression model, only four factors were significantly associated with depression; advancing age, predominately rightside involvement, sleep

disturbance and higher daily dose of levodopa. Findings of this study strongly predicted depression in PD patients was not surprising. The close relationship among these factors is well known in depression with PD.^{24,25,27-31,38,40} It was to be found that the duration of PD symptoms was not related to depression, which supports the idea that depression might be a neuropathological process occurring concomitantly or before the degeneration of motor systems, which is similar with other study.⁴¹

An interesting and surprising finding was that H-Y stage and disability was not associated with depression in multivariate logistic regression model but was significant in univariate analysis. Depression was higher in H-Y stages III and above. Similar findings have been reported previously.^{13,31, 38,45} It was highest in stage IV possibly because this is the stage where the debility becomes marked. Though the rise in the rate of depression would be expected to be linear as the stage and disability increases, this was not observed. This is possibly due to the inability of the severely disabled to physically attend the hospital resulting in a lesser number of patients in severe stages participating in the study which may have influenced the results. The customs of Bangladeshi society, a large number of patients who were caregiver dependent, especially elderly members are cared within a close family network without being hospitalized. Existing views about the association between the severity of PD and depression are contradictory. Some studies reported it as positive, while others showed no association.^{2,17,19,36, 38,49}

Overall findings in relation to the prevalence and factors associated for depression in PD, are in keeping what is reported in Asia and western populations. This study showed some unique association of depression with PD such as higher daily dose of levodopa and predominantly involvement in right side. These findings need further inquiry whether they are replicable regionally or globally. Furthermore, the differences in depression between cultures may

be sought, and studying the phenomenology of depression in PD across cultures may be useful.

Conclusion

Among this population, a significant proportion of PD patients suffer from major depressive disorder. It was identified that depression was significantly associated with a number of socio-demographic and clinical factors including higher daily dose of levodopa, and some other weak factors. In addition, findings of this study displayed some unique features such as depressive vulnerability in the presence of predominate right side involvement and higher daily dose of levodopa. Further studies are suggested, whether there is a regional replicability of these findings and to identify possible underlying mechanisms.

Acknowledgments

Bangladesh Medical Research Council for funding support.

References

1. Samii A, Nutt JG, Ransom BR. Parkinson's disease. *Lancet*.2004; 363: 1783-93.
2. McDonald WM, Richard IH, DeLong MR: Prevalence, etiology, and treatment of depression in Parkinson's disease. *Biol Psychiatry*. 2003;54:363-75.
3. Chen PH, Cheng SJ. Parkinson's disease: Current understanding and treatment. *Int J Gerontology*. 2008; 2: 172-82.
4. Lees AJ, Hardy J, Revesz T. Parkinson's disease. *Lancet*. 2009; 373:2055-66.
5. Alves G, Forsa EB, Pedersen KF, Gjerstad MD, Larsen JP. Epidemiology of Parkinson's disease. *J Neurol*. 2008; 255 [Suppl 5]:18-32.
6. Chaudhuri KR, and Schapira AH. Non-motor symptoms of Parkinson's disease: Dopaminergic pathophysiology and treatment. *Lancet Neurology*.2009; 8: 464-74.
7. Merello M. Non-motor disorders in Parkinson's disease. *Rev Neurol*. 2008;47:261-70.
8. Reijnders JS, Ehrst U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. *Mov Disord*.2008; 23: 183-89.
9. Aarsland D, Bronnick K, Alves G, *et al*. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. *JNNP*.2009; 80: 928-30.
10. Veazey C, Aki SOE, Cook KF, Lai EC, Kunik ME. Prevalence and Treatment of Depression in Parkinson's Disease. *J Neuropsychiatry Clin Neurosci*.2005; 17:310-23.
11. Happe S, Schrvdl B, Faltl M, *et al*. Sleep disorders and depression in patients with Parkinson's disease. *Acta Neurol Scand* 2001; 104:275-80.
12. Nilsson FM. Parkinson's disease and affective disorder: The temporal relationship. *Open Journal of Psychiatry*.2012; 2: 96-109.
13. Rickards H. Depression in neurological disorders: Parkinson's disease, multiple sclerosis, and stroke. *JNNP*. 2005; 76 (Suppl 1): 148-52.
14. Pankratz N, Marder KS, Halter CA, Rudolph A, Shults CW, Nichols WC, Foroud T: Clinical correlates of depressive symptoms in familial Parkinson's disease. *Mov Disord*. 2008, 23:2216-23.
15. Chaudhuri KR, Naidu Y. Early Parkinson's disease and non-motor issues. *J Neurol*. 2008;255 (Suppl 5):S33-S38.
16. Hoogendijk WJG, Sommer IEC, Tissingh G, *et al*. Depression in Parkinson's disease: the impact of symptom overlap on prevalence. *Psychosomatics*.1998; 39:416-21.
17. Marsh L: Neuropsychiatric aspects of Parkinson's disease. *Psychosomatics*.2000; 41:15-23.
18. Carod-Artal FJ, Vargas AP, Martinez-Martin P. Determinants of quality of life in Brazilian patients with Parkinson's disease. *Mov Disord*.2007; 22: 1408-15.
19. Cummings JL, Masterman DL. Depression in patients with Parkinson's disease. *Int J Geria Psychi*. 1999; 14: 711-18.
20. Pontone GM, Williams JR, Anderson KE *et al*. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease. *Mov Disord*. 2009; 24:1333-38.
21. Lieberman A. Depression in Parkinson's disease. *Acta Neurol Scand*.2006; 113: 1-8.
22. Bader JP, Hell D. Parkinson's disease and depression. *Fortschritte-der-Neurologie-Psychiatrie*.1998; 66: 303-12.
23. Dissanayaka NN, O'Sullivan JD, Silburn PA, Mellick GD. Assessment methods and factors associated with depression in Parkinson's disease. *J Neurol Sci*.2011; 310: 208-10.
24. Schrag A, Jahanshahi M, Quinn NP. What contributes to depression in Parkinson's disease? *Psychological Medicine*.2001; 31:65-73.
25. Farabaugh AH, Locascia JJ, Yap L, *etal*. Assessing depression and factors possibly associated with depression during the course of Parkinson's disease. *Ann Clin Psychiatry*.2011; 23:171-77.
26. Schrag A, Barone P, Brown RG, *et al*. Depression Rating Scales in Parkinson's Disease: Critique and Recommendations. *Mov Disord*.2007; 22: 1077-109.

27. Cole SA, Woodard JL, Juncos JL, Kogos JL, Youngstrom EA, Watts RL. Depression and disability in Parkinson's disease. *J Neuropsychiatry Clin Neurosci.* 1996; 8:20-25.
28. Slawek J, Derejko M, Lass P. Factors affecting the quality of life of patients with idiopathic Parkinson's disease—a cross-sectional study in outpatient clinic attendees. *Parkinsonism Relat Disord.* 2005; 11:465-68.
29. Dissanayaka NN, Sellbach A, Silburn PA, *et al.* Factors associated with depression in Parkinson's disease. *J Affect Disord* 2011; 132:82-88.
30. Wichowicz HM, Slawek J, Derejko M, Cubala WJ. Factors associated with depression in Parkinson's disease: a cross-sectional study in a Polish population. *Eur Psychiatry.* 2006; 21:516-20.
31. Tandberg E, Larsen JP, Aarsland D, Laake K, Cummings JL. Risk Factors for Depression in Parkinson Disease. *Arch Neurol.* 1997; 54: 625-30.
32. Shulman LM, Taback RL, Rabinstein AA, *et al.* Non-recognition of depression and other non-motor symptoms in Parkinson's disease. *Parkinsonism Relat Disord.* 2002; 8:193-97.
33. Turčáni P, Benetin J, Cibulčík F. Depression in Parkinson's disease in Slovak population. *Move Disord.* 2013; 28 (Suppl 1):353.
34. Storch A, Ebersbach G, Fuchs G, *et al.* Depression in Parkinson's disease. Epidemiology, signs and symptoms, pathophysiology and diagnosis. *Fortschr Neurol Psychiatr.* 2008; 76: 715-24.
35. Rojo A, Aguilar M, Garolera MT *et al.* Depression in Parkinson's disease: clinical correlates and outcome. *Parkinsonism Relat Disord.* 2003; 10: 23-28.
36. Menza MA, Mark MH. Parkinson's disease and depression: the relationship to disability and personality. *J Neuropsychiatry Clin Neurosci.* 1994; 6:165-69.
37. Daniel SE, Lees AJ: Parkinson's disease society brain bank. London: overview and research. *J Neural Transm.* 1993, 39:165–72.
38. Ketharanathan T, Hanwella R, Weerasundera R and de Silva VA: Major depressive disorder in Parkinson's disease: a cross-sectional study from Sri Lanka. *BMC Psychiatry.* 2014, 14:278.
39. Yamanishi T, Tachibana H, Oguru M, Matsui K, Toda K, Okuda B, Oka N: Anxiety and depression in patients with Parkinson's disease. *Intern Med.* 2013, 52:539–545.
40. Arun MP, Bharath S, Pal PK, Singh G: Relationship of depression, disability, and quality of life in Parkinson's disease: a hospital-based case-control study. *Neurol India.* 2011, 59:185–189.
41. Yapiciesser H, Bora HA, Kuruoglu A. Depression and Parkinson disease: prevalence, temporal relationship, and determinants. *Turk J Med Sci.* 2017; 47: 499-503
42. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. *Lancet Neurol.* 2006; 5: 75-86.
43. Aarsland D, Pahlhagen S, Ballard CG, Ehrst U, Svenningsson P: Depression in Parkinson disease—epidemiology, mechanisms and management. *Nat Rev Neurol.* 2012, 11:35–47.
44. Hong H, Kim BS, Im HI. Pathophysiological role of neuroinflammation in neurodegenerative diseases and psychiatric disorders. *Int Neurol J.* 2016; 20 (Suppl.1): S2-S7.
45. Liu CY, Wang SJ, Fuh JL, Lin CH, Yang YY, Liu HC: The correlation of depression with functional activity in Parkinson's disease. *J Neurol.* 1997, 244:493 – 498.
46. Tandberg E, Larsen JP, Aarsland D, Cummings JL: The occurrence of depression in Parkinson's disease. A community-based study. *Arch Neurol.* 1996, 53:175–79.
47. Hsu YT, Liao CC, Chang SN, Yang YW, Tsai CH, Chen TL, Sung FC. Increased risk of depression in patients with Parkinson's disease: a nationwide cohort study. *Am J Geriatr Psychiatry.* 2015; 23: 934-40.
48. Gustafsson H, Nordström A, Nordström P. Depression and subsequent risk of Parkinson disease: a nationwide cohort study. *Neurology* 2015; 84: 2422-29.
49. Ehmann TS, Beninger RJ, Gawel MJ, Riopelle RJ: Depressive symptoms in Parkinson's disease: a comparison with disabled control subjects. *J Geriatr Psychiatry Neurol.* 1990, 3:3–9.
50. Starkstein SE, Merello M, Jorge R, *et al.* A validation study of depressive syndromes in Parkinson's disease. *Mov Disord.* 2008; 23:538–46.
51. Hoehn MM, Yahr MD: Parkinsonism: onset, progression and mortality. *Neurology* 1967, 17:427-42.
52. Quinn TJ, Dawson J, Walters MR, Lees KR. Variability in modified Ranking scoring across a large cohort of international observers. *Stroke.* 2008; 39:2975-79 .

*Correspondence: Mohammad Ibrahim Khalil, Assistant Professor, Department of Neurology, Shaheed Suhrawardy Medical College and Hospital, Sher-E-Bangla Nagar, Dhaka, Bangladesh; e-mail: ibrahimbd98@yahoo.com